In this report, using a sample of convenience from the Combining Medications to Enhance Depression Outcomes (CO-MED) trial, we evaluated if pre-treatment S100B levels differentially predicted response to escitalopram monotherapy versus combinations of escitalopram plus bupropion or venlafaxine plus mirtazapine. The gene discussed is S100B; the disease is major depressive disorder.